Related Experiment Video
Updated: May 31, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Infant deaths due to heparin overdose: time for a concerted action on prevention
Paul Monagle1, David M Studdert, Fiona Newall
1Department of Clinical Haematology, The Royal Children's Hospital, Melbourne, Victoria, Australia. paul.monagle@rch.org.au
Insights
Heparin use in children needs safer practices. Despite research on its use, many fatal heparin errors occur, highlighting the urgent need for strategies to prevent infant deaths.
Area of Science:
- Pediatric pharmacology and patient safety.
- Anticoagulant therapy in children.
Background:
- Heparin is a widely used anticoagulant in pediatric tertiary care centers.
- Significant research has focused on evidence-based recommendations for pediatric heparin use and management.
- There is a notable lack of focus on improving the safe administration of heparin in children.
Purpose of the Study:
- To highlight the critical need for improved strategies to ensure the safe use of heparin in infants and children.
- To address the disparity between research on heparin efficacy and research on heparin safety in pediatric populations.
Main Methods:
- Review of existing literature and reported incidents concerning heparin use in pediatric patients.
- Analysis of the gap in research focusing on safety protocols versus therapeutic guidelines for pediatric heparin administration.
Main Results:
- Numerous fatal and non-fatal heparin-related errors in pediatric patients have been reported.
- Despite advancements in understanding heparin's therapeutic applications, preventable errors continue to pose significant risks.
Conclusions:
- There is an urgent and unmet need for coordinated efforts to develop and implement strategies for minimizing heparin-related errors in infants and children.
- Concerted action is required to improve patient safety and prevent avoidable deaths associated with heparin therapy in pediatric care.
Abstract:
Heparin is one of the most commonly used drugs in tertiary paediatric centres. Across the last decade, targeted research has been directed towards improving the level of evidence supporting paediatric-specific recommendations for the use and management of heparin in infants and children. In contrast, little effort has been directed towards improving the safe use of heparin despite a plethora of fatal and non-fatal heparin-related errors being reported in the lay press. This short report highlights the need for united and concerted action to develop strategies aimed at minimising avoidable infant deaths related to heparin errors.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pharmaceutical Poisoning: Potential Scenarios
Venous Thrombosis III: Interprofessional Care
Pharmaceutical Poisoning: Treatment Strategies
Drug Regulation
Drug Dosing: Infants and Children

